Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

Data support the Company’s lead investigational product candidate sparsentan SAN DIEGO , Oct. 26, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present data from its sparsentan programs, including long-term clinical

View Full Press Release